^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    huCART19

    i
    Other names: huCART19, huCTL019, huCART-19 T cell therapy, CTL119, CTL 119, CTL-119
    Associations

    News

    Trials
    Company:
    Novartis, University of Pennsylvania
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    5ms
    Retreatment With CTL019/CTL119 (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Pennsylvania | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jul 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    Kymriah (tisagenlecleucel-T) • huCART19
    1year
    Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov)
    P2, N=106, Completed, University of Pennsylvania | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    huCART19
    over1year
    CAR-T Cell Therapy for Desensitization in Kidney Transplantation (clinicaltrials.gov)
    P1, N=20, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • huCART19
    over1year
    CAR-T Cell Therapy for Desensitization in Kidney Transplantation (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Initiation date: Mar 2024 --> May 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • huCART19
    almost2years
    Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
    P1/2, N=93, Recruiting, Stephan Grupp MD PhD | Trial completion date: Jan 2026 --> Jan 2029 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD22 (CD22 Molecule)
    |
    CD19 expression • CD22 expression
    |
    CART22 • huCART19
    almost2years
    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) (clinicaltrials.gov)
    P1/2, N=89, Recruiting, Stephan Grupp MD PhD | Trial completion date: Sep 2027 --> Sep 2029 | Trial primary completion date: Sep 2025 --> Sep 2027
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    huCART19
    2years
    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) (clinicaltrials.gov)
    P1/2, N=89, Recruiting, Stephan Grupp MD PhD | Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2023 --> Sep 2025
    Enrollment open • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    huCART19
    over2years
    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) (clinicaltrials.gov)
    P1/2, N=89, Active, not recruiting, Stephan Grupp MD PhD | Recruiting --> Active, not recruiting
    Enrollment closed • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    huCART19
    over2years
    Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | N=63 --> 100
    Enrollment closed • Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    huCART19
    almost3years
    Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
    P1/2, N=93, Recruiting, Stephan Grupp MD PhD | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CRP (C-reactive protein)
    |
    CD19 expression
    |
    CART22 • huCART19
    almost3years
    Academic Development of a Lentiviral Vector vs CD19 (EHA-EBMT-CART 2023)
    The extracellular domain that we will use corresponds to the mouse monoclonal antibody that recognizes human CD19 from tisagenlecleucel®. It is feasible to develop a huCART-19 with research grade in Mexico, the next step is to evaluate its function in a clinical model.
    IO biomarker • Viral vector
    |
    CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Kymriah (tisagenlecleucel-T) • huCART19
    almost3years
    Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
    P1/2, N=93, Not yet recruiting, Stephan Grupp MD PhD
    New P1/2 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CRP (C-reactive protein)
    |
    CD19 expression
    |
    CART22 • huCART19